Case Filed: Sep 27, 2012
Case Closed: Sep 09, 2013
Court: New Jersey District Court
Judge: Jose L. Linares
Case Summary:
A patent infringement suit was
filed by MSD against Sandoz as a result of the latter filing an abbreviated new
drug application (ANDA) with FDA concerning their intent to market a generic
version of Zetia, used to treat high cholesterol. The patents involved in suit
are:
- RE37721 entitled Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents issued on May 28, 2002 and expires* by Sep 21, 2013
- US5846966 entitled Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors issued on Dec 08, 1998 and expires* by Sep 21, 2013
- US7612058 entitled Methods for inhibiting sterol absorption issued on Nov 03, 2009 and expires* by Sep 21, 2013
- RE42461 entitled Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents issued on Jun 14, 2011and expires* by Jun 14, 2028
- US7030106 entitled Sterol absorption inhibitor compositions issued on Apr 18, 2006 and expires* by Jan 25, 2022
The patents are currently
assigned+
to MSD (source: MaxVal’s Assignment
Database). MSD alleged that Sandoz’s abbreviated new drug application no. 203-931
to manufacture a generic version of Zetia, filed with FDA had the infringed the
above mentioned patents, all of which cover the composition of the drug.
MSD currently holds± the new drug application (NDA) no.
21-445 (source: MaxVal’s Patent
Marker), approved by FDA for 10 mg ezetimibe tablets on October 25, 2002,
which is sold under the trade name Zetia. It is used to treat high cholesterol,
along with a low-fat, low-cholesterol diet. It is sometimes given with other
cholesterol-lowering medications. It is also used to treat high blood
sitosterol and campesterol along with diet therapy. Plaintiffs wanted judgment
that defendant has infringed the patents and an injunction barring their
products until expiration of the patents, along with costs and expenses.
The Court rendered its final
verdict pursuant to the parties agreeing upon a consent judgment. The Judge
ordered:
- Claims, counterclaims are dismissed without prejudice
- Defendant is enjoined from manufacturing/ marketing a generic version of Zetia until April 25, 2017
- Parties to bear their own costs and expense
See 2:12-cv-06077 for
more details. To get alerts on cases filed/closed, subscribe to our Litigation Alerts.
Are you looking for a tool to calculate patent terms? Try Patent
Term Estimator, our free tool or download our free Android app on Google Play
Store.
* Expected expiration date. Patent Term Estimator is a free web-based tool that
automatically calculates patent terms and expiration dates for U.S. utility
patents.
+
MaxVal offers Patent Assignment
Alert service where subscribers receive email alerts when assignments relating
to target applications, patents or entities of interest are recorded.
± Patent Marker provides an online environment where patentees can
virtually mark products and search products for patent-related information.
No comments:
Post a Comment